-
Innovation Ranking
NewInnovation Ranking – Novavax Inc
Novavax Inc (Novavax) is a biotechnology company that discovers, develops and commercializes vaccines to prevent a wide range of infectious diseases. The company develops genetically-engineered vaccine candidates harnessing three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Its pipeline products include NVX-CoV2373 for coronavirus, NanoFlu for seasonal influenza, ResVax for respiratory syncytial syndrome and vaccines indicated for the prevention of Ebola virus, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). It is also developing proprietary immune stimulating...
-
Product Insights
NewNet Present Value Model: Novavax Inc’s NanoFlu
Empower your strategies with our Net Present Value Model: Novavax Inc's NanoFlu report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Novavax Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Novavax Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewNet Present Value Model: Bristol-Myers Squibb Co’s Afimetoran
Empower your strategies with our Net Present Value Model: Bristol-Myers Squibb Co's Afimetoran report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Seasonal Influenza Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Seasonal Influenza Clinical Trial Report Overview A total of 310 seasonal influenza clinical trials were conducted as of February 2024. The Seasonal Influenza clinical trial report provides a comprehensive understanding of the seasonal influenza clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North America ·       ...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – QNIV in Influenza A Virus, H1N1 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QNIV in Influenza A Virus, H1N1 Subtype Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. QNIV in Influenza A Virus, H1N1 Subtype Infections...
-
Sector Analysis
mRNA Vaccines in Infectious Diseases Market Outlook and Trends by Opportunities, Challenges, Unmet Needs, and Competitive Landscape
mRNA Vaccines in Infectious Diseases Market Report Overview The first mRNA vaccines for COVID-19 gained authorization for use in December 2020. These vaccines have been proven highly successful clinically and commercially, dominating the COVID-19 vaccine market. Furthermore, the success of the COVID-19 mRNA vaccines has renewed interest in mRNA vaccines for a variety of other infectious diseases such as influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), Mpox, herpes, Zika virus, and Lyme disease. The report provides an assessment of the...
-
Product Insights
Seasonal Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Seasonal Influenza - Drugs In Development, 2023’, provides an overview of the Seasonal Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Severe Acute Respiratory Syndrome (SARS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Severe Acute Respiratory Syndrome (SARS) - Drugs In Development, 2023’, provides an overview of the Severe Acute Respiratory Syndrome (SARS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Influenza A Virus, H5N1 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H5N1 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H5N1 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...